PureTech Presents New Data from Phase 2b Open-Label Extension Study of Deupirfenidone (LYT-100), Further Supporting Strong and Durable Efﬁcacy and Potential to Serve as New Standard of Care in IPF

deupirfenidone (LYT-100) - PureTech

Sep 29, 2025